2021年WHO肺癌分类:分子生物学研究与影像-病理相关性
2021年WHO胸部肿瘤分类对肺癌有多项更新,包括浸润性非黏液性腺癌新分级系统、鳞状细胞癌和神经内分泌肿瘤的重组及新实体描述。分子检测范围从2015年推荐的EGFR突变和ALK融合扩展到ROS1、RET、NTRK1-3、KRAS、BRAF、MET等,并推荐转移性非小细胞肺癌一线治疗前检测PD-L1。由于70%肺癌初诊时不可切除,诊断多基于小活检标本而非手术切除标本,放射科医生在评估肿瘤和转移灶及确定最佳活检靶点方面起关键作用。
要点
- 2021 WHO肺浸润性非黏液性腺癌新分级系统能更好地反映预后。
- 非鳞状非小细胞肺癌基因检测从EGFR/ALK扩展到ROS1、RET、NTRK1-3、KRAS、BRAF、MET等。
- 70%肺癌初诊时不可切除,诊断多基于小活检标本,需注意小标本与切除标本组织病理判读差异。
核心结论
- 2021年WHO肺癌分类更新了腺癌分级、肿瘤分类和新实体,强调分子检测范围扩大及小活检标本诊断的重要性,放射科医生在评估肿瘤、转移灶和确定最佳活检靶点中起关键作用。
研究设计与样本
- 指南/共识解读(2021年WHO胸部肿瘤分类更新),基于2015年版分类的修订,由WHO发布。
诊断标准与关键数值
- 2015年指南推荐非鳞状非小细胞肺癌患者仅评估EGFR突变和ALK融合两种驱动基因;2021年指南推荐检测更多可用靶向治疗的基因突变,包括ROS1、RET、NTRK1-3、KRAS、BRAF和MET;推荐转移性非小细胞肺癌患者一线治疗前检测免疫生物标志物PD-L1。
临床应用与阅片要点
- 放射科医生在评估肿瘤和转移性疾病以及确定最佳活检靶点方面起关键作用。
- 由于70%肺癌初诊时不可切除,诊断通常基于小诊断样本(即活检标本)而非手术切除标本,2021版强调小诊断样本与切除标本组织病理判读的差异。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The 2021 World Health Organization (WHO) classification system for thoracic tumors (including lung cancer) contains several updates to the 2015 edition. Revisions for lung cancer include a new grading system for invasive nonmucinous adenocarcinoma that better reflects prognosis, reorganization of squamous cell carcinomas and neuroendocrine neoplasms, and description of some new entities. Moreover, remarkable advancements in our knowledge of genetic mutations and targeted therapies have led to a much greater emphasis on genetic testing than that in 2015. In 2015, guidelines recommended evaluation of only two driver mutations, ie, epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusions, in patients with nonsquamous non-small cell lung cancer. The 2021 guidelines recommend testing for numerous additional gene mutations for which targeted therapies are now available including ROS1, RET, NTRK1-3, KRAS, BRAF, and MET. The correlation of imaging features and genetic mutations is being studied. Testing for the immune biomarker programmed death ligand 1 is now recommended before starting first-line therapy in patients with metastatic non-small cell lung cancer. Because 70% of lung cancers are unresectable at patient presentation, diagnosis of lung cancer is usually based on small diagnostic samples (ie, biopsy specimens) rather than surgical resection specimens. The 2021 version emphasizes differences in the histopathologic interpretation of small diagnostic samples and resection specimens. Radiologists play a key role not only in evaluation of tumor and metastatic disease but also in identification of optimal biopsy targets. ©RSNA, 2024 Test Your Knowledge questions in the supplemental material and the slide presentation from the RSNA Annual Meeting are available for this article.
引用
- Sasaki T, Kuno H, Hiyama T, et al. 2021 WHO Classification of Lung Cancer: Molecular Biology Research and Radiologic-Pathologic Correlation. Radiographics. 2024. PMID: 38358935. doi:10.1148/rg.230136
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。